TITLE

Cannabinoids did not reduce muscle spasticity in stable multiple sclerosis: COMMENTARY

AUTHOR(S)

Weinshenker, Brian G.

PUB. DATE

May 2004

SOURCE

ACP Journal Club;May/Jun2004, Vol. 140 Issue 3, p69

SOURCE TYPE

Academic Journal

DOC. TYPE

Article

ABSTRACT

It has been suggested that marijuana has a beneficial effect on various MS-related symptoms, including spasticity, pain, and tremor. A survey in Canada, reported that 43% of 420 responders to a survey, had tried marijuana, 16% for medicinal purposes. The study is larger and, hence, more powerful than the previous studies of cannabinoids in MS. Patients in this trial were using other antispasticity drugs and physical therapy treatments, albeit at a stable dose or regimen. The study did not attempt to address the effectiveness of cannabinoids relative to conventional antispasticity drugs. Blinding was successful for the assessor but not for the treating neurologist or patients. No effect on the primary spasticity outcome, the Ashworth score, was observed.

ACCESSION #

13221840

 

Related Articles

• Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled, crossover study. Vaney, C.; Heinzel-Gutenbrunner, M.; Jobin, P.; Tschopp, F.; Gattlen, B.; Hagen, U.; Schnelle, M.; Reif, M. // Multiple Sclerosis (13524585);Aug2004, Vol. 10 Issue 4, p417 

  Objective: Cannabis may alleviate some symptoms associated with multiple sclerosis (MS). This study investigated the effect of an orally administered standardized Cannabis sativa plant extract in MS patients with poorly controlled spasticity. Methods: During their inpatient rehabilitation...

• Effect of low doses of ?9-tetrahydrocannabinol and cannabidiol on the extinction of cocaine-induced and amphetamine-induced conditioned place preference learning in rats. Parker, Linda A.; Burton, Page; Sorge, Robert E.; Yakiwchuk, Christine; Mechoulam, Raphael // Psychopharmacology;2004, Vol. 175 Issue 3, p360 

  Presents a study which evaluated the potential of the two most prominent cannabinoids found in marijuana, the psychoactive component Δ 9 -tetrahydrocannabinol and the nonpsychoactive component cannabidiol to potentiate extinction of a cocaine-induced and an amphetamine-induced conditioned...

• Marijuana researchers reach for pot of gold. Mandavilli, Apoorva // Nature Medicine;Oct2003, Vol. 9 Issue 10, p1227 

  Presents updates on studies on the therapeutic use and other physiological effects of marijuana. Number of active compounds in cannabis sativa; Description of cannabinoid receptors; Delivery technologies for cannabis; Study of cannabidiol the second biggest ingredient in cannabis and the least...

• Developing Pharmacotherapies for Cannabis and Cocaine Use Disorders. Hart, Carl L.; Lynch, Wendy J. // Current Neuropharmacology;Apr2005, Vol. 3 Issue 2, p95 

  Despite the fact that more people seek treatment for cannabis-related disorders than for any other illicit substance-related disorder in the U.S., there are no medications approved for the treatment of these disorders. Similarly, more than half of those meeting criteria for a cocaine use...

• Pharmacological and therapeutic targets for ?9 tetrahydrocannabinol and cannabidiol. Pertwee, Roger // Euphytica;Jun2004, Vol. 140 Issue 1/2, p73 

  Cannabis is the unique source of a set of at least 66 compounds known collectively as cannabinoids. Of these, most is known about the pharmacology of ?9-tetrahydrocannabinol (?9-THC), the main psychoactive constituent of cannabis, and about cannabidiol (CBD), which lacks psychoactivity....

• Inducing the Munchies - THC for Cancer Cachexia. Greenfield, Russell H. // Alternative Medicine Alert;Apr2011, Vol. 14 Issue 4, p43 

  PEOPLE WITH ADVANCED CANCER FREQUENTLY REPORT LOSS of interest in food, an altered taste of their favorite dishes, and diminished appetite. The authors of this randomized, double-blind, placebo-controlled 22-day Phase 2 pilot study sought to determine whether a synthetic form of marijuana...

• How our brains fend off madness. Nowak, Rachel // New Scientist;8/28/2004, Vol. 183 Issue 2462, p13 

  A cannabis-like substance produced by the brain may dampen delusional or psychotic experiences, rather than trigger them. Heavy cannabis use has been linked to psychosis in the past, leading researchers to look for a connection between the brain's natural cannabinoid system and schizophrenia....

• Long-Term Effects of Cannabis on Brain Structure. Battistella, Giovanni; Fornari, Eleonora; Annoni, Jean-Marie; Chtioui, Haithem; Dao, Kim; Fabritius, Marie; Favrat, Bernard; Mall, Jean-Frédéric; Maeder, Philippe; Giroud, Christian // Neuropsychopharmacology;Aug2014, Vol. 39 Issue 9, p2041 

  The dose-dependent toxicity of the main psychoactive component of cannabis in brain regions rich in cannabinoid CB1 receptors is well known in animal studies. However, research in humans does not show common findings across studies regarding the brain regions that are affected after long-term...

• Simultaneous and Sensitive Analysis of THC, 11-OH-THC, THC-COOH, CBD, and CBN by GC-MS in Plasma after Oral Application of Small Doses of THC and Cannabis Extract. Nadulski, Thomas; Sporkert, Frank; Schnelle, Martin; Stadelmann, Andreas Michael; Roser, Patrik; Schefter, Tom; Pragst, Fritz // Journal of Analytical Toxicology;Nov/Dec2005, Vol. 29 Issue 8, p782 

  The article discusses the development of a method for the simultaneous quantitative determination of Δ9-tetrahydrocannabinol (THC), its metabolites 11-hydroxy-Δ9-tetrahydrocannabinol and 11-nor-9-carboxy-Δ9-tetrahydrocannabinol, cannabidiol (CBD) and cannabinol (CBN) from plasma. The...

Read the Article